In a study, the treatment was associated with a 53% decreased risk of death from kidney cancer compared with expectant management.
Bevacizumab, sorafenib, and temsirolimus combinations did not improve progression-free survival in renal cell carcinoma (RCC).
80% of lung cancer deaths linked to smoking, researchers say.
Asymptomatic presentation, T3 low-grade tumors, and negative lymph nodes are associated with better progression-free and overall survival.
Study findings contradict those of previous investigators.
Two-thirds of patients feel that tumor profiling could improve their treatment; many will pay out of pocket.
Data suggest that a 7% or 8% cut-off rather than the conventional 30% is a better predictor in patients treated for mRCC.
RCC tumor shrinkage significantly and independently predicted overall survival.
Neoadjuvant sunitinib was linked to primary tumor and thrombus shrinkage, reduced blood loss during surgery, as well as improved cancer-specific survival.
Pathological stage was the only independent factor linked to kidney cancer progression.
The approach was defined as surgical resection with a wide margin or radiotherapy with a biologically effective dose of 140 Gy or greater.
In a study, patients who had the procedure had a better 5-year overall survival rate than those who did not (68% vs. 27%).
New finding may inform treatment decisions.
It is important to assess factors that may put patients at higher risk of metastatic disease, according to researchers.
In a study, treatment could have been avoided in at least 26% of cases because a biopsy revealed a benign lesion, researchers reported.
Current practice of only focusing on tumor samples might adversely affect care.
Lapascopic and percutaneous cryoablation for small renal masses are associated with similar survival, researchers say.
Research raises concern about the simultaneous use of chemotherapy and fish oil.
The risk is particularly elevated for patients who have CKD risk factors, such as hypertension, diabetes, and older age.
Urine aquaporin-1 and perilipin-2 may have utility as biomarkers for diagnosing malignant clear cell or papillary renal cell carcinoma (RCC).
Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
However, researchers stress that losing excess weight can lower the cancer odds.
Patients with these risk factors should be followed up for the rest of their lives, according to the researchers.
Overweight or obese patients treated with targeted therapy for metastatic clear-cell renal cell carcinoma found to live longer.
In a study of 4,736 patients with metastatic renal cell carcinoma, use of the drugs was associated with a nearly 22% decreased risk of death.
Sorafenib or sunitinib given after surgery for advanced renal cell carcinoma does not improve progression-free survival, study shows.
Researchers found elevated familial risks for testicular, prostate, bladder, and kidney cancers.
Risk factors include male gender, distant disease, increasing age, race/ethnicity
Data reveal no significant differences in overall and cancer-specific survival at 5 years.
- Complications More Likely After Radiotherapy vs. Surgery for PCa
- Metformin Use in Advanced CKD Raises Death Risk
- Cholecalciferol May Be Superior for Treating Vitamin D Deficiency
- Heparin-Lidocaine Combo Relieves Interstitial Cystitis Symptoms
- Laparoscopically Harvesting Right Kidneys from Living Donors Safe
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)